Invivyd, Inc. Form 8-K Summary
Reporting date: December 6, 2022. The filing reports executive leadership and compensation matters under Item 5.02, other organizational announcements under Item 8.01, and related exhibits under Item 9.01. Invivyd is a Delaware biotechnology company whose common stock trades on Nasdaq under the symbol IVVD.
Business Context and Reporting Period
The filing does not provide quarterly or annual financial results. It announces the appointment of Jeremy Gowler as Chief Operating Officer and Chief Commercial Officer, effective December 16, 2022. The filing states that the Board appointed him to these roles on September 16, 2022.
Financial Metrics and Liquidity
- Revenue, profit or loss, cash flow, margins, debt, cash balance, liquidity, and other operating metrics: the filing text does not provide clear values.
- No financing, capital-raising, debt, or liquidity transaction is disclosed.
Material Changes and Executive Compensation
- Mr. Gowler brings approximately 20 years of senior commercial experience in the pharmaceutical and biotechnology industries, including roles at Sandoz, Novartis, PaxVax, and Emergent BioSolutions.
- Annual base salary: $440,000, subject to periodic review and adjustment.
- One-time signing bonus: $150,000, payable within 30 days after the effective date and earned on the 12-month anniversary, subject to potential repayment provisions.
- Initial target annual cash bonus: 40% of annual base salary, subject to performance goals and Compensation Committee determination. He is eligible for his full 2022 target opportunity despite joining late in the year, although the amount paid remains subject to committee discretion.
- Equity award: an option to purchase 625,000 shares of common stock at an exercise price equal to the December 16, 2022 closing sales price. Twenty-five percent vests on the first anniversary, with the remainder generally vesting monthly over the following three years, subject to continued service.
Severance, Outlook, and Other Matters
- Outside the change-in-control period, a qualifying termination without cause or for good reason may entitle Mr. Gowler to nine months of base salary, any earned bonus, nine months of benefit continuation, and limited continuation of unvested time-based equity awards.
- During the defined change-in-control period, a qualifying termination may provide 12 months of base salary, the target bonus for the termination year, any earned bonus, 12 months of benefit continuation, and full acceleration of time-based equity awards, subject to execution of a release.
- Mr. Gowler also entered into an indemnification agreement and the Company’s proprietary information and inventions assignment agreement, including confidentiality, noncompetition, and nonsolicitation provisions.
- The Company issued a December 6, 2022 press release announcing Mr. Gowler’s appointment and other organizational changes, but the filing text does not describe the additional changes in detail.
- No guidance, forecast, clinical update, contingency, litigation matter, or unusual financial item is disclosed in the provided text.
Investor Verification Items
- Verify the complete employment agreement filed as Exhibit 10.1, including definitions of cause, good reason, and change in control.
- Confirm the exercise price and final terms of the 625,000-share option based on the December 16, 2022 closing price.
- Review the Exhibit 99.1 press release for the other organizational changes referenced in the filing.
- Consult the Company’s financial filings for current revenue, operating losses, cash runway, liquidity, debt, and development-program status, none of which are provided in this 8-K.